{"id":42818,"date":"2017-05-10T07:51:30","date_gmt":"2017-05-10T05:51:30","guid":{"rendered":"https:\/\/renewable-carbon.eu\/news\/?p=42818"},"modified":"2017-05-09T12:28:06","modified_gmt":"2017-05-09T10:28:06","slug":"royal-dsm-to-make-equity-investment-in-amyris-with-the-purpose-of-establishing-a-long-term-relationship","status":"publish","type":"post","link":"https:\/\/renewable-carbon.eu\/news\/royal-dsm-to-make-equity-investment-in-amyris-with-the-purpose-of-establishing-a-long-term-relationship\/","title":{"rendered":"Royal DSM to make equity investment in Amyris with the purpose of establishing a long-term relationship"},"content":{"rendered":"

Amyris, Inc. (Nasdaq: AMRS), the industrial bioscience company, and Koninklijke DSM N.V. (Royal DSM) (AEX: DSM.AS), the global science-based company active in health, nutrition and materials, today announced that they have agreed for DSM to make an equity investment in Amyris<\/a>. At the same time, the companies will enter into a development cooperation focused on products for the global health and nutrition markets (including vitamins and other nutritional ingredients).<\/strong><\/p>\n

Amyris\u2019 technology supports DSM\u2019s strategic markets in health, nutrition, and materials as well as a growing consumer shift to (bio-) natural-like products derived from sustainable sources. For Amyris, DSM\u2019s channels and market access and keen understanding in selecting the right products for the animal nutrition, human nutrition, and consumer health markets provide strategic value.<\/p>\n

Equity Investment<\/h3>\n

DSM has agreed to make an initial equity investment in Amyris of US$25 million, translating into a shareholding of ~12%. Subject to the satisfaction of certain conditions, DSM may invest an additional US$25 million in Amyris. The first tranche is expected to close on Thursday, 11 May 2017, with a second tranche, if approved by DSM\u2019s Managing Board, expected to close within 90 days of the closing of the first tranche. As part of this investment, DSM will gain one board seat upon the closing of each tranche.<\/p>\n

As part of the agreement, DSM and Amyris have agreed to focus on a number of short- to medium-term product development & production opportunities in vitamins and other nutritional ingredients.<\/p>\n

\u201cWe are very excited about DSM\u2019s strategic focus in health and nutrition markets and its commitment to sustainable sourcing and production of better-performing products,\u201d said John Melo, Amyris President & CEO. \u201cThe Amyris technology platform and potential synergy can lead to significant cost improvements for DSM while accelerating Amyris\u2019s market access. We expect this will lead to incremental revenue in 2017, growing annually based on the number of products we develop in our partnership and our pace of delivery.\u201d<\/p>\n

\u201cAmyris has a unique yeast-based strain engineering platform that is very complementary to DSM\u2019s capabilities in this area and will create great synergy with DSM\u2019s know-how in fermentation, downstream process development and large-scale manufacturing,\u201d said Chris Goppelsroeder, President & CEO of DSM Nutritional Products. \u201cWorking closely together with Amyris and leveraging DSM\u2019s route-to-market, will accelerate our innovation towards cost-effective, fermentation-based processes for both existing and new products.”<\/p>\n

Terms of the private placement and related agreements are more fully disclosed in the Form 8-K filed by Amyris today with the Securities and Exchange Commission, available free of charge at sec.gov<\/a>.<\/p>\n

About Amyris<\/h3>\n

Amyris is the integrated renewable products company that is enabling the world\u2019s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise\u00ae<\/sup> products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Development cooperation focused on products for the global health and nutrition markets<\/p>\n","protected":false},"author":58,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"","nova_meta_subtitle":"","footnotes":""},"categories":[5572],"tags":[5838,5829],"supplier":[2389,12205],"class_list":["post-42818","post","type-post","status-publish","format-standard","hentry","category-bio-based","tag-bioeconomy","tag-economy","supplier-amyris","supplier-dsm"],"_links":{"self":[{"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/posts\/42818","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/users\/58"}],"replies":[{"embeddable":true,"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/comments?post=42818"}],"version-history":[{"count":0,"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/posts\/42818\/revisions"}],"wp:attachment":[{"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/media?parent=42818"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/categories?post=42818"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/tags?post=42818"},{"taxonomy":"supplier","embeddable":true,"href":"https:\/\/renewable-carbon.eu\/news\/wp-json\/wp\/v2\/supplier?post=42818"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}